Faruqi & Faruqi, LLP Alerts Inovio Pharmaceuticals Investors of Class Action Deadlines

Investor Alert: Inovio Pharmaceuticals Class Action

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued a reminder to investors of Inovio Pharmaceuticals (NASDAQ: INO) regarding an important deadline related to a securities class action lawsuit. The deadline for investors to seek the role of lead plaintiff in this case is April 7, 2026.

The firm is currently probing potential claims against Inovio Pharmaceuticals, which has come under scrutiny for its actions and disclosures regarding its manufacturing processes and regulatory submissions. As a shareholder, if you purchased or acquired securities in Inovio between October 10, 2023, and December 26, 2025, it’s crucial to be aware of your legal rights in this complex situation.

Background on the Inovio Situation

The investigation centers around alleged violations of federal securities laws. According to the allegations, Inovio and its executives made false or misleading statements concerning the manufacturing quality of the CELLECTRA device. This misrepresentation has raised concerns about the company's ability to meet crucial regulatory requirements with the FDA.

In late December 2025, significant news broke when the FDA accepted Inovio's Biologics License Application (BLA) for INO-3107, a treatment aimed at recurrent respiratory papillomatosis. However, it became evident that the information submitted did not support eligibility for the accelerated approval that the company sought. This revelation led to a substantial drop in the company's stock price, underscoring the market's reaction to the FDA's assessment of Inovio's submission.

Despite these challenges, the firm claims it has a strategy for moving forward, despite the setback. The FDA indicated that Inovio did not qualify for the expedited review process, raising concerns about its future prospects and potential approval timelines.

What Investors Should Do

Faruqi & Faruqi encourages affected investors to reach out and discuss their options. The firm emphasizes that being a lead plaintiff is significant; however, any investor retains the right to join the class action without taking an active role in the litigation. Potential lead plaintiffs must demonstrate their financial interest in the outcome of the lawsuit and must be typical of the class members.

If you have information relevant to this case, including whistleblowers or former employees, Faruqi & Faruqi wants to hear from you. Investors should consider consulting with legal professionals specializing in securities litigation to navigate this situation effectively.

As the April 7, 2026 deadline approaches, it’s imperative for stakeholders to stay informed and proactive in their actions regarding this impending class action suit. For more information, investors can visit the firm's website or contact Josh Wilson directly at Faruqi & Faruqi. They can provide insights into how shareholders may be affected and the best steps to take moving forward.

For additional updates and information, follow Faruqi & Faruqi on their social media platforms or visit their official website.